Have a feature idea you'd love to see implemented?
Let us know!
ANAB Anaptysbio Inc
Price (delayed)
$22.265
Market cap
$611.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.35
Enterprise value
$556.28M
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients
Highlights
The company's gross profit has surged by 136% YoY and by 33% QoQ
ANAB's revenue has soared by 136% YoY and by 33% from the previous quarter
Anaptysbio's equity has plunged by 93% YoY and by 79% from the previous quarter
ANAB's EPS is down by 22% year-on-year and by 3.4% since the previous quarter
Key stats
What are the main financial stats of ANAB
Market
Valuations
Earnings
Shares outstanding
27.45M
Market cap
$611.16M
Enterprise value
$556.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
61.57
Price to sales (P/S)
19.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.25
Revenue
$30.47M
EBIT
-$170.11M
EBITDA
-$167.71M
Free cash flow
-$129.9M
Per share
Balance sheet
Liquidity
EPS
-$6.35
Free cash flow per share
-$4.75
Book value per share
$0.36
Revenue per share
$1.11
TBVPS
$15.62
Total assets
$427.38M
Total liabilities
$417.5M
Debt
$16.95M
Equity
$9.88M
Working capital
$326.93M
Debt to equity
1.72
Current ratio
9.09
Quick ratio
8.9
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
-550.4%
Gross margin
100%
Net margin
-558.2%
Operating margin
-532.9%
Return on assets
-38.4%
Return on equity
-255.7%
Return on invested capital
-45.2%
Return on capital employed
-44%
Return on sales
-558.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANAB stock price
How has the Anaptysbio stock price performed over time
Intraday
-27.71%
1 week
-35.93%
1 month
-33.54%
1 year
35.02%
YTD
3.94%
QTD
-33.54%
Financial performance
How have Anaptysbio's revenue and profit performed over time
Revenue
$30.47M
Gross profit
$30.47M
Operating income
-$162.39M
Net income
-$170.12M
Gross margin
100%
Net margin
-558.2%
The company's gross profit has surged by 136% YoY and by 33% QoQ
ANAB's revenue has soared by 136% YoY and by 33% from the previous quarter
The company's operating margin has surged by 51% YoY and by 25% QoQ
ANAB's net margin is up by 50% YoY and by 22% from the previous quarter
Growth
What is Anaptysbio's growth rate over time
Valuation
What is Anaptysbio stock price valuation
P/E
N/A
P/B
61.57
P/S
19.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.25
ANAB's EPS is down by 22% year-on-year and by 3.4% since the previous quarter
Anaptysbio's equity has plunged by 93% YoY and by 79% from the previous quarter
ANAB's revenue has soared by 136% YoY and by 33% from the previous quarter
The stock's price to sales (P/S) is 21% less than its 5-year quarterly average of 35.1 and 3.4% less than its last 4 quarters average of 28.6
Efficiency
How efficient is Anaptysbio business performance
Anaptysbio's return on equity has shrunk by 58% QoQ
The return on invested capital has dropped by 56% year-on-year and by 13% since the previous quarter
The ROA has shrunk by 53% YoY and by 9% QoQ
ANAB's return on sales is up by 50% year-on-year and by 22% since the previous quarter
Dividends
What is ANAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANAB.
Financial health
How did Anaptysbio financials performed over time
The total assets is 2.4% more than the total liabilities
The company's quick ratio fell by 21% QoQ and by 14% YoY
The current ratio has declined by 21% since the previous quarter and by 14% year-on-year
ANAB's debt is 72% more than its equity
Anaptysbio's equity has plunged by 93% YoY and by 79% from the previous quarter
ANAB's debt is down by 9% YoY and by 2.5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.